Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Fate Therapeutics announced five presentations featuring their innovative iPSC-derived off-the-shelf CAR T-cell therapy platform at the upcoming ASGCT Annual Meeting in New Orleans. The highlight is an oral presentation on FT522, their groundbreaking CD19-targeted CAR NK cell product for B-cell lymphoma treatment.
Key developments include:
- First product incorporating Alloimmune Defense Receptor (ADR) technology, designed to eliminate the need for conditioning chemotherapy
- Four additional poster presentations covering applications in autoimmune diseases, hematological malignancies, and solid tumors
- Introduction of FT836, a novel MICA/B-targeting CAR T-cell therapy for solid tumors
The presentations will showcase both clinical and preclinical data, demonstrating the company's progress in developing chemotherapy-free cell therapies across multiple indications.
Fate Therapeutics ha annunciato cinque presentazioni che illustrano la loro innovativa piattaforma di terapia CAR T-cell off-the-shelf derivata da iPSC al prossimo incontro annuale ASGCT a New Orleans. Il momento clou sarà una presentazione orale su FT522, il loro rivoluzionario prodotto CAR NK cell mirato a CD19 per il trattamento del linfoma a cellule B.
Sviluppi principali includono:
- Primo prodotto che integra la tecnologia Alloimmune Defense Receptor (ADR), progettata per eliminare la necessità di chemioterapia di condizionamento
- Quattro ulteriori presentazioni poster che trattano applicazioni in malattie autoimmuni, neoplasie ematologiche e tumori solidi
- Presentazione di FT836, una nuova terapia CAR T-cell mirata a MICA/B per tumori solidi
Le presentazioni mostreranno dati clinici e preclinici, dimostrando i progressi dell'azienda nello sviluppo di terapie cellulari senza chemioterapia per diverse indicazioni.
Fate Therapeutics anunció cinco presentaciones que destacan su innovadora plataforma de terapia CAR T celular derivada de iPSC y lista para usar en la próxima Reunión Anual de ASGCT en Nueva Orleans. El punto culminante será una presentación oral sobre FT522, su revolucionario producto CAR NK dirigido a CD19 para el tratamiento del linfoma de células B.
Desarrollos clave incluyen:
- Primer producto que incorpora la tecnología Alloimmune Defense Receptor (ADR), diseñada para eliminar la necesidad de quimioterapia de acondicionamiento
- Cuatro presentaciones adicionales en formato póster que cubren aplicaciones en enfermedades autoinmunes, malignidades hematológicas y tumores sólidos
- Introducción de FT836, una novedosa terapia CAR T celular dirigida a MICA/B para tumores sólidos
Las presentaciones mostrarán datos clínicos y preclínicos, demostrando el progreso de la compañía en el desarrollo de terapias celulares sin quimioterapia para múltiples indicaciones.
Fate Therapeutics가 뉴올리언스에서 열리는 다가오는 ASGCT 연례회의에서 혁신적인 iPSC 유래 오프더셸프 CAR T 세포 치료제 플랫폼을 소개하는 다섯 건의 발표를 발표했습니다. 하이라이트는 B세포 림프종 치료를 위한 획기적인 CD19 표적 CAR NK 세포 제품인 FT522에 대한 구두 발표입니다.
주요 개발 내용은 다음과 같습니다:
- 조절 화학요법의 필요성을 없애기 위해 설계된 Alloimmune Defense Receptor (ADR) 기술을 적용한 첫 제품
- 자가면역 질환, 혈액암 및 고형암에 대한 적용을 다루는 네 건의 추가 포스터 발표
- 고형암 치료를 위한 새로운 MICA/B 표적 CAR T 세포 치료제인 FT836 소개
발표에서는 임상 및 전임상 데이터를 통해 여러 적응증에 걸쳐 화학요법 없는 세포 치료제 개발에서 회사의 진전을 보여줄 예정입니다.
Fate Therapeutics a annoncé cinq présentations mettant en avant leur plateforme innovante de thérapie CAR T-cellules dérivée d'iPSC prête à l'emploi lors de la prochaine réunion annuelle de l'ASGCT à la Nouvelle-Orléans. Le point fort sera une présentation orale sur FT522, leur produit révolutionnaire de cellules CAR NK ciblant CD19 pour le traitement du lymphome à cellules B.
Les développements clés incluent :
- Premier produit intégrant la technologie Alloimmune Defense Receptor (ADR), conçue pour éliminer le besoin de chimiothérapie de conditionnement
- Quatre présentations supplémentaires sous forme de posters couvrant des applications dans les maladies auto-immunes, les malignités hématologiques et les tumeurs solides
- Introduction de FT836, une nouvelle thérapie CAR T-cellules ciblant MICA/B pour les tumeurs solides
Les présentations mettront en lumière des données cliniques et précliniques, démontrant les progrès de l'entreprise dans le développement de thérapies cellulaires sans chimiothérapie pour plusieurs indications.
Fate Therapeutics kündigte fünf Präsentationen an, die ihre innovative iPSC-abgeleitete Off-the-Shelf CAR T-Zelltherapie-Plattform auf dem bevorstehenden ASGCT-Jahrestreffen in New Orleans vorstellen. Das Highlight ist eine mündliche Präsentation zu FT522, ihrem bahnbrechenden CD19-zielgerichteten CAR NK-Zellprodukt zur Behandlung von B-Zell-Lymphomen.
Wichtige Entwicklungen umfassen:
- Erstes Produkt mit Alloimmune Defense Receptor (ADR)-Technologie, entwickelt, um die Notwendigkeit einer Konditionierungschemotherapie zu eliminieren
- Vier weitere Posterpräsentationen zu Anwendungen bei Autoimmunerkrankungen, hämatologischen Malignomen und soliden Tumoren
- Einführung von FT836, einer neuartigen CAR T-Zelltherapie, die MICA/B für solide Tumoren anvisiert
Die Präsentationen werden sowohl klinische als auch präklinische Daten zeigen und den Fortschritt des Unternehmens bei der Entwicklung chemotherapiefreier Zelltherapien für verschiedene Indikationen demonstrieren.
- First-in-class iPSC-derived CAR T-cell therapy platform showcasing potential across multiple indications (autoimmune, cancer)
- FT522 achieves milestone as first product with Alloimmune Defense Receptor (ADR) technology in Phase 1 clinical trials
- ADR technology could eliminate need for conditioning chemotherapy, potentially reducing treatment costs and complications
- Broad pipeline development across multiple therapeutic areas (autoimmune disease, hematological malignancy, solid tumors)
- Multiple data presentations at major scientific conference (ASGCT) indicating strong scientific validation
- Still in early clinical stages with no approved products
- Heavy reliance on single technology platform (iPSC-derived therapies)
- Competitive field in CAR-T cell therapy development
- No efficacy or safety data disclosed in the press release
Insights
Fate Therapeutics announces upcoming presentations of clinical and preclinical data at ASGCT, showcasing progress in their iPSC-derived cell therapy platform.
Fate Therapeutics' announcement about their five upcoming presentations at the ASGCT Annual Meeting represents meaningful progress in their development pipeline. The company will present both clinical and preclinical data from their induced pluripotent stem cell (iPSC) platform, with a notable focus on their FT522 Phase 1 trial in relapsed/refractory B-cell lymphoma.
The key technological advancement highlighted is their Alloimmune Defense Receptor (ADR) technology, designed to reduce or eliminate conditioning chemotherapy for patients receiving cell therapies. This approach addresses a significant limitation in current cell therapy treatments, as conditioning chemotherapy carries substantial toxicity risks for patients.
The breadth of their development efforts is impressive, spanning autoimmune diseases, hematological malignancies, and solid tumors. The selection of their work for an oral presentation suggests scientific peer recognition of their approach and data. However, it's important to recognize that this announcement doesn't contain actual results - just that the data will be presented at the conference.
For context, the FT522 program represents the first clinical application of their ADR technology, making the Phase 1 data particularly significant as an initial validation of their platform approach. Their iPSC-derived off-the-shelf CAR T-cell therapies could potentially offer advantages over current autologous cell therapies if they demonstrate comparable efficacy with improved manufacturing consistency and elimination of conditioning regimens.
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients, today announced that five presentations of clinical and preclinical data from the Company’s induced pluripotent stem cell (iPSC) product platform will be featured at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held in New Orleans, Louisiana on May 13-17, 2025.
The Company has been selected to deliver an oral presentation on the translational data from its Phase 1 clinical trial of FT522, an off-the-shelf, CD19-targeted CAR NK cell product candidate, in patients with relapsed / refractory B-cell lymphoma (BCL) (NCT05950334). FT522 is the first product candidate to incorporate Alloimmune Defense Receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of conditioning chemotherapy to patients receiving cell therapies. In addition, the Company will highlight preclinical data from its off-the-shelf, iPSC-derived, CAR T-cell product platform across autoimmune disease, hematological malignancy and solid tumor indications.
Accepted abstracts are available on the ASGCT Annual Meeting website. Presentation details are as follows:
Oral Presentation
Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy
Session: Innovation in Alternative Cell Therapy Sources
Location: Room 391-392
Presentation Date / Time: Saturday, May 17, 2025, 11:00 AM CT
Poster Presentations
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
Poster Number: 758
Presentation Date / Time: Tuesday, May 13, 2025, 6:00 PM CT
Targeting UPAR With Multiplexed-Engineered iPSC-Derived CAR T Cells to Reverse Age- and Insult-Related Fibrotic Disease
Poster Number: 789
Presentation Date / Time: Tuesday, May 13, 2025, 6:00 PM CT
Next-Generation Off-the-Shelf CAR T-Cell Therapies for Conditioning-Free Treatment of a Broad Spectrum of Autoimmune Diseases and Hematologic Malignancies
Poster Number: 1259
Presentation Date / Time: Wednesday, May 14, 2025, 5:30 PM CT
FT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor Indications
Poster Number: 1229
Presentation Date / Time: Wednesday, May 14, 2025, 5:30 PM CT
About Fate Therapeutics’ iPSC Product Platform
Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the initiation and continuation of enrollment in the Company’s clinical trials, the timing and availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, and the potential capabilities and benefits of the Company’s iPSC product platform. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
What are the 5 presentations Fate Therapeutics (FATE) is showcasing at ASGCT 2025?
How does Fate Therapeutics' FT522 CAR NK cell therapy work without conditioning chemotherapy?
What is the significance of Fate Therapeutics' iPSC platform for off-the-shelf cell therapy?
When is Fate Therapeutics (FATE) presenting at ASGCT 2025?
What types of diseases can Fate Therapeutics' CAR T-cell therapies target?
